KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Co-Diagnostics (CODX) Common Equity (2017 - 2025)

Historic Common Equity for Co-Diagnostics (CODX) over the last 9 years, with Q3 2025 value amounting to $39.8 million.

  • Co-Diagnostics' Common Equity fell 3755.76% to $39.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.8 million, marking a year-over-year decrease of 3755.76%. This contributed to the annual value of $54.3 million for FY2024, which is 3685.66% down from last year.
  • Per Co-Diagnostics' latest filing, its Common Equity stood at $39.8 million for Q3 2025, which was down 3755.76% from $41.1 million recorded in Q2 2025.
  • In the past 5 years, Co-Diagnostics' Common Equity registered a high of $147.7 million during Q1 2022, and its lowest value of $39.8 million during Q3 2025.
  • For the 5-year period, Co-Diagnostics' Common Equity averaged around $91.4 million, with its median value being $87.3 million (2021).
  • In the last 5 years, Co-Diagnostics' Common Equity soared by 29785.88% in 2021 and then crashed by 4317.72% in 2025.
  • Co-Diagnostics' Common Equity (Quarter) stood at $134.5 million in 2021, then fell by 14.84% to $114.5 million in 2022, then dropped by 24.89% to $86.0 million in 2023, then tumbled by 36.86% to $54.3 million in 2024, then decreased by 26.67% to $39.8 million in 2025.
  • Its last three reported values are $39.8 million in Q3 2025, $41.1 million for Q2 2025, and $47.9 million during Q1 2025.